Among the numerous methods available, GLP-1 (glucagon-like peptide-1) drugs have gained popularity for their effectiveness in aiding weight loss
Key Takeaways Retatrutide remains investigational and is not routine clinical treatment
White concluded her remarks by saying, The findings add to a growing body of evidence suggesting GLP-1 receptor agonists may have broader neurologic and anti-inflammatory effects beyond weight loss alone. While more research is needed before GLP-1s can be recommended as a migraine therapy, this study offers the promise that semaglutide might also ease the burden of migraine for many females.
Medical supervision helps confirm candidacy, guide dosing, monitor side effects, protect nutrition intake and adjust treatment when needed
Results The sample had a mean age of 50.8 years (SD=13.2) and was 81% female
MOTS-c was evaluated in relation to obesity and osteoporosis, but the committees favorable recommendation did not approve it for weight loss or place it on the same evidence level as an FDA-approved obesity medication